Exicure Inc

NASDAQ:XCUR   10:03:52 AM EDT
1.55
+0.01 (+0.65%)
Regulatory, Earnings Announcements

Exicure Presents Interim Results From Ongoing Phase 1B/2 Trial Of Cavrotolimod

Published: 09/16/2020 11:36 GMT
Exicure Inc (XCUR) - Exicure Presents Promising Interim Results From Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual Kol Event Today.
Exicure Inc - Confirmed Orr 21% (4/19 Patients) Overall in Phase 1b Dose-escalation Stage of Cavrotolimod.
Exicure - Median Duration of Response Not Been Reached As All 4 Confirmed Responders Not Progressed After 11 Months Median Follow-up in Cavrotolimod Trial.
Exicure - Continues to Observe Cavrotolimod is Well Tolerated With 98% of All Treatment-emergent Adverse Events Assessed As Grade 1 Or 2 in Severity.
Exicure Inc - No Treatment-related Serious Adverse Events Were Reported to Date in Cavrotolimod Trial.
Exicure Inc - Expects to Provide Interim Orr Results From Mcc and Cscc Cohorts of Phase 2 Portion of Clinical Trial in First Half of 2021.
Exicure Inc - Expects to Provide Final Orr Results From Mcc and Cscc Cohorts of Phase 2 Portion of Clinical Trial by Year End 2021.
Revenue is expected to be $1.64 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $1.64 Million
Next Quarter EPS Guidance is expected to be -$0.14

More details on our Analysts Page.